Pulse Biosciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; filed March 12, 2021. Although the request identifies Q4 2020, this is an annual filing and the provided text does not give standalone Q4 financial results.
Business context
Pulse Biosciences is a pre-revenue medical technology company developing the CellFX System, which uses its Nano-Pulse Stimulation (NPS) technology to target cells while aiming to spare surrounding non-cellular tissue. Its initial commercial focus is aesthetic and medical dermatology. The company reported no product revenue through year-end 2020.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $50.0 million | $48.0 million |
| Research and development | $26.4 million | $25.0 million |
| General and administrative | $22.9 million | $22.3 million |
| Net loss | $49.9 million | $47.0 million |
| Net loss per share, basic and diluted | $2.14 | $2.26 |
| Net cash used in operating activities | $35.4 million | $34.2 million |
Gross and operating margins are not meaningful because the company had no revenue. The net loss increased by $2.9 million year over year as expenses rose and interest income fell by $0.9 million, chiefly because average investment balances were lower. Stock-based compensation was $10.1 million, down from $11.3 million.
At December 31, 2020, cash and cash equivalents were $12.5 million and investments were $8.0 million, totaling $20.5 million. Current assets were $22.3 million and current liabilities were $7.6 million. Total liabilities were $18.4 million, including $11.4 million of operating lease liabilities; the balance sheet shows no borrowing outstanding at year-end. Cash provided by financing was $30.9 million, principally the $29.4 million net proceeds from the June 2020 rights offering. Cash increased $5.6 million during the year.
Material changes and developments
- Operating expenses rose $2.0 million, including higher personnel, paid services, and facility costs, partly offset by lower external research, prototype costs, travel, and stock-based compensation.
- The June 2020 rights offering issued 4.28 million common shares and 641,571 warrants for $29.4 million net proceeds. Chairman Robert W. Duggan participated and owned approximately 47% of common stock at year-end.
- After year-end, the company received FDA 510(k) clearance in February 2021 for a general dermatologic indication and received EU CE marking in January 2021. It began controlled launches in the U.S. and EU in February 2021.
- The company completed treatment in an investigational pivotal study of sebaceous hyperplasia in January 2021 and planned a specific-indication 510(k) submission. It also submitted a medical-device license application in Canada in November 2020.
Outlook, risks and unusual items
Management said year-end cash and investments were expected to fund projected operating requirements for at least 12 months from the filing date, while also stating that it expects to raise additional capital. In February 2021, the company established an at-the-market equity program of up to $60 million. In March 2021, after year-end, it entered into an unsecured $41 million term-loan facility from Mr. Duggan, bearing 5% annual interest, increasing to 7% upon specified events, and maturing June 11, 2022. The loan contains covenants and default provisions.
Key risks include continued operating losses and cash burn, dependence on external financing, uncertain adoption and utilization of CellFX, competition, clinical and regulatory uncertainty for additional indications, manufacturing and supplier reliance, reimbursement uncertainty, and possible COVID-19 effects on trials, operations, and suppliers. The company reported no serious adverse events in its dermatology clinical studies to date, but clinical and commercial outcomes remain uncertain. It reported no pending legal matter it believed would have a material adverse effect.
An unusual related-party arrangement followed the company’s decision not to renew its directors’ and officers’ liability insurance because of high premiums. Mr. Duggan agreed to provide substantially similar personal indemnity coverage for one year, backed by $30 million in cash security; the company accrued a $1.6 million amount payable at year-end toward a $2.5 million fee due in May 2021. Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2020; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether CellFX launches translate into recurring system and per-treatment revenue, and the pace of physician adoption and utilization.
- Actual cash burn, remaining liquidity, and use of the $60 million ATM program and $41 million Duggan loan, including loan covenants and maturity obligations.
- Regulatory progress for specific indications, particularly sebaceous hyperplasia, and the final results and limitations of clinical studies.
- Potential dilution from future equity sales, outstanding warrants and options, and the effects of Duggan’s approximately 47% ownership and related-party financing.
- Whether commercial-scale manufacturing, supplier capacity, and clinical evidence can support growth while containing costs.